What is the recommended treatment for moderate asthma control?

The recommended treatment for achieving moderate asthma control typically involves a combination of a low dose inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA) or a medium dose ICS, with or without the addition of a leukotriene receptor antagonist (LTRA).

Inhaled corticosteroids are essential in managing inflammation within the airways, and when combined with a LABA, they provide effective control of asthma symptoms and improve pulmonary function. This combination therapy addresses both the airway inflammation and bronchoconstriction, making it particularly suitable for patients whose asthma is not adequately controlled with a shorter-acting rescue inhaler alone, such as a short-acting beta-agonist (SABA) taken as needed for symptom relief.

Assigning systemic corticosteroids alone is generally reserved for severe exacerbations or for acute management situations, rather than as a long-term strategy for moderate asthma management. High-dose ICS and the additional treatments like omalizumab are typically considered for more severe cases or uncontrolled asthma that does not respond adequately to lower doses.

In summary, the structured approach to managing moderate asthma includes the use of low or medium-dose ICS in combination with LABA or LTRA to achieve effective control, making this option the most